EQL Pharma

Carl Lindgren has more than 30 years of experience in the pharmaceutical industry and comes most recently from a role as Vice President M&A/BD at Karo Healthcare (formerly Karo Pharma), which during Carl's time has grown from approx. SEK 350m to approx. 4.5bn in annual turnover. In addition to having been deeply involved in Karo Healthcare's organic growth, Carl has also been responsible for and carried out a number of successful acquisitions.

"EQL is an entrepreneurial company in rapid and profitable growth. I look forward to becoming part of a successful team and to contributing to the continued positive development of the company," says Carl Lindgren.

"With his solid experience and network, Carl is perfect for the role of CBDO in the phase EQL is now entering, with an increased focus on expansion into non-Nordic European markets and profitable synergistic acquisitions." says Axel Schörling, CEO at EQL Pharma. "At the same time, our increasingly large portfolio of products leads to a growing need for commercial efforts to maximize their potential and Alexander, who held similar roles at previous employers, is the right man to lead this".

Carl Lindgren takes up his position as CBDO at EQL in August 2023.